Petr Arenberger
Prague, PR, Czech Republic
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 128 publications
primary analysis of the RANDOMIZED eortc-2139/columbus-ad trial: Adjuvant encorafenib and binimetinib versus placebo in high-risk stage II BRAF-V600E/K melanoma.
Journal: European journal of cancer (Oxford, England : 1990)
Published: April 16, 2026
European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention - Update 2026.
Journal: European journal of cancer (Oxford, England : 1990)
Published: March 19, 2026
European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment - update 2026.
Journal: European journal of cancer (Oxford, England : 1990)
Published: March 19, 2026
Nivolumab for Resected Stage III or IV Melanoma at 9 Years.
Journal: The New England journal of medicine
Published: October 22, 2025
Comparison of the Efficacy and Safety between Adjuvant and Palliative Anti-PD-1 Treatment of Stage 4 Oligometastatic Melanoma.
Journal: Dermatology practical & conceptual
Published: July 14, 2025
Erratum: Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 25, 2025
Efficacy of radiotherapy in stabilization of oligoprogressive lesions of malignant melanoma treated with immunotherapy.
Journal: Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology
Published: May 29, 2025
Messages for ultraviolet-radiation protection to fair-skinned populations.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: May 28, 2025
Super-Response to Guselkumab Treatment in Patients With Moderate-to-Severe Psoriasis: Real-World Data With Up to Five Years of Follow-Up in The Czech Republic.
Journal: International journal of dermatology
Published: May 21, 2025
Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 06, 2025
Prognostic Biomarkers for Anti-PD-1 Monoclonal Antibodies in the First Line Treatment of Advanced Melanoma.
Journal: International journal of dermatology
Published: January 04, 2025
Highly selective, allosteric inhibition of TYK2 with oral ESK-001 in patients with moderate-to-severe plaque psoriasis: Results from STRIDE, a 12-week, randomized, double-blinded, placebo-controlled, dose-ranging phase 2 study.
Journal: Journal of the American Academy of Dermatology
Published: December 20, 2024
Last Updated: 09/26/2026